Boston Scientific Corporation Boston Scientific Corporation

Boston Scientific Corporation

BSX

株式のランク #409

この企業概要は英語でのみ提供されています。

Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
株価
$41.88
最終同期: 2026-10-30
時価総額
$60.69B
変化(1日)
-1.89%
変化(1年)
-58.42%
国
US

株式データ: Financial Modeling Prep·更新日: ·投資助言ではありません·計算方法

カテゴリー

Healthcare
Boston Scientific Corporation(BSX)の配当利回りの履歴
Boston Scientific Corporation(銘柄コード: BSX)の配当利回り(TTM)は2025時点で0.00%です。
過去5年間の平均配当利回り: 0.04%
Boston Scientific Corporation(BSX)の2000から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
年 配当利回り 変化
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% -100.00%
2023 0.03% -62.50%
2022 0.08% -11.11%
2021 0.09% 80.00%
2020 0.05% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% 0.00%
2001 0.00% 0.00%
2000 0.00% 0.00%
類似企業または競合他社の配当利回り(TTM)

Boston Scientific Corporationの配当利回りに関する質問

Boston Scientific Corporationの2025年の配当利回りはどのくらいでしたか?

2025年のBoston Scientific Corporationの配当利回りは0.00%で、2024年は0.00%でした。

Boston Scientific Corporationの配当利回りは2020年以降どのように推移していますか?

2020年から2025年までのBoston Scientific Corporationの配当利回りは、2021年(0.09%)が最も高く、2025年(0.00%)が最も低くなっています。

Boston Scientific Corporationの配当利回りは類似企業と比べてどうですか?

Boston Scientific Corporationの配当利回りは0.00%で、上に挙げた類似企業5社のすべてを下回っています。これらの企業の中で最も高いのはMedtronic plcで、2.96%です。